Table 1.
Baseline demographic characteristics for adults in EBL2002, EBL2004,a and EBL3001 (per-protocol analysis set).
| Study | N | Age, years |
Sex, n (%)b |
Body-mass index, kg/m2 |
|||
|---|---|---|---|---|---|---|---|
| Median (IQR) | Male | Female | Median (IQR) | ||||
| EBL2002 | Cohort 1 (healthy adults and elderly) | Vaccine | 137 | 31.0 (24.0; 42.0) | 89 (65) | 48 (35) | 22.6 (20.5; 25.4) |
| Burkina Faso | 40 | 29.0 (22.5; 38.5) | 27 (68) | 13 (33) | 21.4 (20.1; 24.9) | ||
| Côte d’Ivoire | 18 | 37.0 (33.0; 40.0) | 17 (94) | 1 (6) | 23.5 (22.1; 25.8) | ||
| Kenya | 20 | 29.0 (22.5; 48.0) | 9 (45) | 11 (55) | 22.5 (20.3; 27.6) | ||
| Uganda | 59 | 29.0 (23.0; 44.0) | 36 (61) | 23 (39) | 23.1 (21.0; 26.0) | ||
| Control | 24 | 30.0 (24.5; 34.0) | 15 (63) | 9 (38) | 21.1 (20.0; 24.5) | ||
| Burkina Faso | 6 | 30.5 (30.0; 31.0) | 4 (67) | 2 (33) | 20.7 (19.6; 22.0) | ||
| Côte d’Ivoire | 3 | 23.0 (23.0; 47.0) | 2 (67) | 1 (33) | 23.4 (19.3; 25.3) | ||
| Kenya | 5 | 22.0 (21.0; 31.0) | 3 (60) | 2 (40) | 20.3 (19.0; 20.7) | ||
| Uganda | 10 | 29.5 (27.0; 37.0) | 6 (60) | 4 (40) | 22.5 (20.8; 25.1) | ||
| EBL2002 | Cohort 2a (HIV-infected) | Vaccine | 59 | 39.0 (36.0; 44.0) | 17 (29) | 42 (71) | 23.7 (20.1; 27.5) |
| Control | 12 | 41.5 (38.0; 46.5) | 2 (17) | 10 (83) | 23.1 (21.8; 27.4) | ||
| EBL2004 | Vaccine | 256 | 28.0 (22; 41) | 136 (53) | 120 (47) | 22.6 (20.6; 26.5) | |
| Guinea | 87 | 30.0 (23.0; 44.0) | 35 (40) | 52 (60) | 23.7 (21.2; 28.5) | ||
| Liberia | 67 | 28.0 (21.0; 40.0) | 41 (61) | 26 (39) | 22.4 (20.6; 28.2) | ||
| Mali | 49 | 28.0 (22.0; 40.0) | 28 (57) | 21 (43) | 22.8 (20.3; 28.8) | ||
| Sierra Leone | 53 | 26.0 (19.0; 46.0) | 32 (60) | 21 (40) | 21.5 (20.3; 23.5) | ||
| Control | 122 | 29.0 (22; 40) | 64 (53) | 58 (48) | 22.6 (20.6; 25.6) | ||
| Guinea | 44 | 29.5 (23.0; 40.0) | 23 (52) | 21 (48) | 22.5 (20.5; 26.1) | ||
| Liberia | 33 | 24.0 (22.0; 34.0) | 16 (49) | 17 (52) | 23.3 (21.8; 24.6) | ||
| Mali | 25 | 31.0 (20.0; 40.0) | 11 (44) | 14 (56) | 22.9 (20.4; 30.3) | ||
| Sierra Leone | 20 | 30.5 (22.5; 45.5) | 14 (70) | 6 (30) | 21.7 (20.2; 24.1) | ||
| EBL3001 | Stage 1 | Vaccine | 43 | 23.0 (20.0; 27.0) | 42 (98) | 1 (2) | 21.9 (20.6; 22.9) |
| Stage 2 | Vaccine | 191 | 23.0 (21.0; 30.0) | 160 (84) | 31 (16) | 21.6 (19.8; 22.9) | |
| Control | 68 | 24.0 (20.5; 35.0) | 56 (82) | 12 (18) | 21.3 (20.1; 22.8) | ||
HIV; Human immunodeficiency virus, IQR; Interquartile range.
a
One participant in the per-protocol set is excluded from this table as the participant had data at month 1 but not at month 3 and month 12.
b
Percentages may not add up to 100 due to rounding.